<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">
LSX-Blog.png

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Infographic: C-suite challenges in life sciences 2...

In early 2017, LSX, formerly Biotech and Money, published the inaugural Inv...

Read More

Biotech and Money rebrands to reflect wider life s...

Biotech and Money is now LSX – The network for life science executive leade...

Read More

Technical notices for a ‘no-deal’ Brexit

The UK government issued a series of ‘technical notices’ on 23 August outli...

Read More

CMR Surgical prepares for commercialisation on the...

Key findings: In June 2018, surgical robotics company CMR Surgical raised $...

Read More

Endomag secures £8m Series C for scale up

Key learnings: UK and US-based Endomag raised £8 million through its Series...

Read More

Investorview: Ingredients for growth in life scien...

Industrifonden is an evergreen venture capital fund with headquarters in St...

Read More

Appleyard Lees: Applying in-house expertise to dev...

Key learnings: UK-based Appleyard Lees provides clients worldwide with a fu...

Read More

Nominations for the 2018 life science leaders awar...

The Lifestars Awards bring together over 500 global life science leaders, i...

Read More

Investorview: Plugging knowledge gaps to accelerat...

Venture capital firm Hadean Ventures closed its first fund at the end of 20...

Read More

Investorview: Committing to social responsibility ...

Swiss venture capital firm MTIP launched its first fund in 2016, achieving ...

Read More

SurgaColl’s £3.1m Series A investment to drive nex...

Key learnings: SurgaColl announced the completion of a £3.1 million Series ...

Read More

Carmell Therapeutics advances plasma-based product...

Key learnings: Carmell™ Therapeutics closed its Series B round in June 2017...

Read More

Add Your Response